Les Newsletters de Stop-Tabac.ch

Webmasters - Proposez nos news sur votre site

Rechercher dans les anciennes newsletter:

29 janvier 2013

La newsletter de stop-tabac: les sujets clés de l?actualité mondiale sur le tabagisme

Sélection réalisée par Jean-François Etter

Le 29 janvier 2013


- Questionnaire sur la cigarette électronique
- Un médecin à portée de clavier
- Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.
- Chattez avec un médecin tabacologue


Questionnaire sur la cigarette électronique

Si vous avez déjà utilisé une cigarette électronique, veuillez répondre à notre nouveau questionnaire sur le sujet. Merci de votre aide ! Cliquez ici:
http://www.stop-tabac.ch/fr_hon/ECIG_2012/ (24 01 2013)
(29 01 2013)


Un médecin à portée de clavier

De nombreux examens médicaux peuvent désormais être pratiqués avec un simple smartphone. Aux Etats-Unis, plusieurs dispositifs sont déjà homologués. Ils devraient bientôt arriver en France. Lire la suite...

http://www.lemonde.fr/sciences/article/2013/01/03/un-medecin-a-portee-de-clavier_1812625_1650684.html#xtor=AL-32280270 (08 01 2013)
(29 01 2013)


Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.

BACKGROUND:

The use of varenicline tartrate alleviates postquit withdrawal discomfort, but it also seems to reduce the "reward" associated with smoking. The current treatment schedule, which commences 1 week before quitting, relies primarily on the first mechanism. We set out to determine whether increasing the prequit medication period renders cigarettes less satisfying and facilitates quitting.

METHODS:

One hundred one smokers attending a stop-smoking clinic in London, United Kingdom, were randomly allocated to receive varenicline for 4 weeks before the target quit date (TQD) or to receive placebo for 3 weeks before the TQD, followed by varenicline for 1 week before the TQD. In both groups, standard varenicline treatment was given for 3 months after the TQD. Measures included smoking satisfaction and smoke intake before quitting, urges to smoke and withdrawal discomfort after quitting, and sustained abstinence from the TQD to 3 months.

RESULTS:

Varenicline preloading reduced prequit enjoyment of smoking (P = .004) and smoke intake (P < .001), with 36.7% of participants reducing their cotinine concentrations by more than 50% (reducers). Varenicline preloading did not affect postquit withdrawal symptoms, but it increased 12-week abstinence rates (47.2% in the varenicline arm vs 20.8% in the placebo arm, P = .005). The effect was particularly strong among the reducers in the varenicline arm (66.7% in reducers vs 22.6% in nonreducers, P = .002). Varenicline preloading was well tolerated.

CONCLUSIONS:

Although several issues remain to be clarified, varenicline preloading can generate a substantial reduction in ad lib smoking and enhance 12-week quit rates. Current treatment schedules may lead to suboptimal treatment results. Trials with longer follow-up periods are needed to corroborate these findings. Trial Registration clinicaltrials.gov Identifier: NCT00789074.

Arch Intern Med. 2011 Apr 25;171(8):770-7. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. (21 06 2011)
(29 01 2013)



Retour à la liste des newsletters